ReviewClinical kidney journal2026
Drowning the kidneys: from fluid overload to physiology-guided fluid management in onco-hematology.
Review in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) is a frequent complication in patients with cancer. Although AKI in oncology is often multifactorial, it is frequently attributed to nephrotoxicity or intrinsic tubular injury. However, its hemodynamic mechanisms remain underrecognized. Accumulating evidence from critical care and cardiorenal medicine indicates that fluid overload, venous congestion, and increased intra-abdominal pressure are major drivers of kidney dysfunction and adverse outcomes in patients with cancer. These mechanisms are particularly relevant in onco-hematology, where protocol-driven hydration, transfusions, systemic inflammation, and capillary leak are common. This review examines venous congestion as an underrecognized and potentially reversible contributor to AKI in patients with cancer, by integrating epidemiological data, mechanistic insights, and clinical evidence. Particular emphasis is placed on the distinction between fluid responsiveness (FR) and fluid tolerance (FT), with the reviewed studies suggesting that many patients with AKI are neither fluid responsive nor fluid tolerant and that these phenotypes evolve dynamically over time. Tumor lysis syndrome is presented as a paradigmatic clinical scenario in which aggressive hydration is widely recommended despite limited high-quality evidence and a substantial risk of fluid intolerance. We further describe the role of point-of-care ultrasound in the bedside assessment of cardiac filling pressures, venous congestion, and stroke volume, and propose a physiology-based framework for AKI evaluation that prioritizes exclusion of urinary tract obstruction, systematic assessment of FT, and selective evaluation of FR in hypotensive or low-flow states. Adopting this approach may help individualize fluid management, reduce iatrogenic harm, and improve renal outcomes in patients with cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.